Of particular note, anti-PD-1 antibody has shown promising anticancer activity with tolerable toxicity profiles in a number of clinical trials5, 7, altering the standard of treatment for melanoma, non-small cell lung cancer and other cancers. This evidence concerns the gene PDCD1 and melanoma.